Archived David Kirn Scientific Publications – 2000

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D. Nature Med. 2000 Oct;6(10):1134-9....

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH. Nature Med. 2000 Aug;6(8):879-85....